Table 3.

Migraine parameters before and after erenumab therapy.

	Before erenumab therapy initiation		During/after erenumab therapy initiation
Migraine parameters	Mean ± SD	Median	Mean ± SD	Median	p-value
1. Number of monthly migraine days	22.00 ± 6.75	21.00	13.00 ± 8.69	11.50	<0.001**
2. Number of missed days (necessity of bed rest or isolation due to migraine)/month	11.75 ± 8.82	10.00	4.12 ± 4.70	2.00	0.001**
3. Number of limited days (patient's productivity was affected due to migraine)/month	9.81 ± 7.03	9.00	8.06 ± 7.69	5.00	0.426
4. Pain intensity [rating from 0 (no pain) to 10 (excruciating pain)]	8.69 ± 1.49	9.00	5.69 ± 1.78	6.00	0.001**
5. Number of acute medication days/month	17.38 ± 7.61	15.00	10.56 ± 9.03	7.50	<0.001**
6. Number of migraine attacks associated with accompanying symptoms (e.g., nausea, vomiting, aura, photophobia/photosensitivity, phonophobia/phonosensitivity, intolerance to smells, pain worsens with movement)/month (n = 14)	12.06 ± 8.63	12.50	6.38 ± 7.59	5.50	0.003**
7. Number of migraine attacks that were free from accompanying symptoms/month	5.86 ± 7.66	2.00	9.14 ± 10.25	5.00	0.138
8. Number of pain-free days/month	7.38 ± 5.62	7.00	15.75 ± 7.56	15.00	<0.001**

^**Significant difference at 1% level of significance.

For each migraine parameter, the mean (SD) and median were calculated. All migraine parameters improved significantly (p < 0.01) except for “number of limited days per month” and “number of migraine attacks free of accompanying symptoms per month” (p > 0.05).